8-K: Cognition Therapeutics Presents Promising Data on CT1812 for Alzheimer's and Other Neurodegenerative Diseases

Cognition Therapeutics highlights positive Phase 2 results for CT1812, an oral drug targeting amyloid oligomers, showing cognitive improvements in Alzheimer's patients and expansion into new indications.

Summary

• Cognition Therapeutics is developing CT1812, an orally administered small molecule designed to antagonize amyloid oligomers, a neurotoxic form of amyloid beta implicated in Alzheimer's disease.
• Phase 2 proof-of-concept data for CT1812 in mild-to-moderate Alzheimer's showed a 40% mean improvement in cognitive measures compared to placebo.
• The SHINE study, a Phase 2 trial, demonstrated a 39% slowing of cognitive decline on the ADAS-Cog 11 scale with pooled CT1812 treatment compared to placebo.
• CT1812 also showed positive trends across other cognitive and functional outcome measures, with a favorable safety profile.
• The company is currently enrolling patients in a Phase 2 trial for early-mild Alzheimer's in collaboration with the Alzheimer's Clinical Trials Consortium (ACTC).
• CT1812 is also being investigated for Dementia with Lewy Bodies (DLB) and Dry Age-related Macular Degeneration (dAMD) with Geographic Atrophy (GA).
• A Phase 2 trial in DLB, called SHIMMER, is expected to have topline results by the end of 2024.
• A Phase 2 trial in dAMD/GA, called MAGNIFY, is actively recruiting patients.
• The company has secured approximately $171 million in grant funding for CT1812 studies, with $57.3 million remaining as of June 30, 2024.
• Cognition Therapeutics' current cash and cash equivalents are $28.5 million, providing a cash runway into the second quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results for CT1812, highlighting its potential as a novel treatment for Alzheimer's and other neurodegenerative diseases. The company has secured significant grant funding and is expanding into new indications. However, the need for future capital raises and the inherent risks of clinical development temper the overall sentiment.

Positives

• CT1812 is an orally administered drug, offering a more convenient alternative to intravenous therapies.
• The drug targets amyloid oligomers, which are considered a key driver of neurodegeneration in Alzheimer's.
• Clinical trials have shown a favorable safety and tolerability profile for CT1812.
• The company has secured significant grant funding to support the development of CT1812.
• CT1812 is being investigated in multiple indications, expanding its potential market.
• The SHINE study results showed a 39% slowing of cognitive decline, which is comparable to or better than some approved monoclonal antibody treatments.
• The company has a cash runway into the second quarter of 2025.

Negatives

• The company's cash and cash equivalents are $28.5 million, which may require additional funding in the future.
• The SHIMMER study in DLB is not powered for statistical significance.
• The company is still in the clinical trial phase, and there is no guarantee of regulatory approval for CT1812.
• The 300mg dose group in the SHINE study had more discontinuations and liver enzyme elevations.

Risks

• The company's ability to successfully advance CT1812 through clinical trials and obtain regulatory approvals is subject to risk.
• There is a risk that the results of earlier-stage clinical trials may not be predictive of later-stage trial results.
• The company faces competition from other companies developing treatments for Alzheimer's and other neurodegenerative diseases.
• The company's ability to secure new grant funding and maintain relationships with suppliers is subject to risk.
• The company's financial position may require additional capital raises in the future.
• The company is subject to risks related to economic uncertainty, global conflicts, and the impact of the COVID-19 pandemic.

Future Outlook

The company expects to continue clinical development of CT1812 across multiple indications, with topline results for the SHIMMER study expected by the end of 2024 and continued enrollment in the MAGNIFY study. The company's cash runway is expected to last into the second quarter of 2025.

Management Comments

• CT1812 is a first-in-class amyloid oligomer antagonist via the sigma-2 receptor.
• The company anticipates a well-tolerated safety profile for CT1812.
• Oral administration of CT1812 offers greater convenience and access compared to intravenous therapies.

Industry Context

The document highlights the significant unmet need in Alzheimer's disease and other neurodegenerative conditions, emphasizing the potential of CT1812 as a novel treatment approach. The focus on amyloid oligomers, rather than plaques, aligns with a growing understanding of the disease's pathology. The comparison to approved monoclonal antibody treatments suggests a competitive landscape where oral therapies like CT1812 could offer advantages.

Comparison to Industry Standards

• The SHINE study results showed a 39% slowing of cognitive decline on the ADAS-Cog 11 scale, which is comparable to or better than the 26% slowing observed with Lecanemab at 18 months in the CLARITY study.
• The company benchmarks its results against Lecanemab and Donanemab, two approved monoclonal antibody treatments for Alzheimer's disease.
• The document notes that CT1812 is an oral therapy, which is a key differentiator from the intravenous administration of monoclonal antibodies.
• The company highlights that CT1812 does not have the risk of ARIA (Amyloid-Related Imaging Abnormalities), a side effect associated with some monoclonal antibody treatments.

Stakeholder Impact

• Shareholders may benefit from the positive clinical trial results and the potential for CT1812 to become a successful treatment.
• Patients with Alzheimer's, DLB, and dAMD/GA may benefit from the development of a new, potentially effective treatment option.
• Employees may benefit from the company's growth and success.
• The company's suppliers and partners may benefit from the continued development of CT1812.

Next Steps

• Continue enrollment in the Phase 2 START study for early Alzheimer's disease.
• Complete the Phase 2 SHIMMER study in Dementia with Lewy Bodies and report topline results by the end of 2024.
• Continue enrollment in the Phase 2 MAGNIFY study for Dry AMD/Geographic Atrophy.
• Advance CT1812 through clinical development and seek regulatory approvals.

Key Dates

Keywords

Alzheimer's disease, amyloid oligomers, CT1812, Dementia with Lewy Bodies, Dry AMD, Geographic Atrophy, clinical trials, neurodegenerative diseases, cognitive decline, oral drug, sigma-2 receptor